Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Jul 2.
Published in final edited form as: ACS Catal. 2020 Jun 17;10(13):7146–7153. doi: 10.1021/acscatal.0c00623

Expanding the chemical space of synthetic cyclic peptides using a promiscuous macrocyclase from prenylagaramide biosynthesis

Snigdha Sarkar , Wenjia Gu , Eric W Schmidt †,*
PMCID: PMC7805243  NIHMSID: NIHMS1657769  PMID: 33457065

Abstract

Cyclic peptides are excellent drug candidates, placing macrocyclization reactions at the apex of drug development. PatG and related dual-action proteases from cyanobactin biosynthesis are responsible for cleaving off the C-terminal recognition sequence and macrocyclizing the substrate to provide cyclic peptides. This reaction has found use in the enzymatic synthesis of diverse macrocycles. However, these enzymes function best on substrates that terminate with the non-proteinogenic thiazole/thiazoline residue, complicating synthetic strategies. Here, we biochemically characterize a new class of PatG-like macrocyclases that natively use proline, obviating the necessity of additional chemical or biochemical steps. We experimentally define the biochemical steps involved in synthesizing the widespread prenylagaramide-like natural products, including macrocyclization and prenylation. Using saturation mutagenesis, we show that macrocyclase PagG and prenyltransferase PagF are highly promiscuous, producing a library of more than 100 cyclic peptides and their prenylated derivatives in vitro. By comparing our results to known cyanobactin macrocyclases, we catalog a series of enzymes from this family that should synthesize most small macrocycles. Collectively, these data reveal that, by selecting the right cyanobactin macrocyclase, a large array of enzymatically synthesized macrocycles are accessible.

Graphical Abstract

graphic file with name nihms-1657769-f0007.jpg

INTRODUCTION

Macrocycles are prevalent in drug development, with a growing number of macrocyclic peptides that are FDA approved or in clinical trials.13 However, the therapeutic scope of cyclic peptides remains underexploited. Synthetic macrocyclizing approaches include metathesis,46 click chemistry,79 the use of auxiliaries,1011 and intein-mediated ligation,12 but despite many innovations limitations remain.13 Enzymes provide an additional tool to create libraries of cyclic peptides for drug discovery. Examples include subtiligase,1415 cyanobactin macrocyclases,16 and cyclotide macrocyclases,1720 each of which has been exploited in drug discovery programs. As with chemical synthesis, each enzyme has its limits, including restricted substrate tolerance, reaction condition requirements, and others. Here, we sought to remedy these limitations by exploring orthogonal cyanobactin macrocyclases for their biotechnological potential.

Cyanobactins are ribosomally synthesized and post-translationally modified peptides (RiPPs) found in cyanobacterial blooms.2122 Most of these compounds are N-C circular, with macrocyclization catalyzed by a unique series of subtilisin-like serine proteases exemplified by PatG from pat pathway.2324 The substrates for PatG are short precursor peptides containing the substrate for macrocyclization and a C-terminal recognition sequence (RS). A unique helix-turn-helix motif in PatG, the capping helix (CH), selectively recognizes the RS and secures the substrate in the active site pocket.25 Subsequently, the PatG active-site serine proteolyzes the substrate, releasing the RS and leaving a covalently captured enzyme-substrate ester. In most serine proteases, a hydrolytic event then releases the substrate as a linear peptide.12 In PatG and relatives, instead of this canonical reaction, the covalent intermediate is captured by the substrate’s own N-terminus, leading to the synthesis of a cyclic peptide (Figure 1).25

Figure 1.

Figure 1.

Proposed reaction mechanism of previously characterized cyanobactin macrocyclases, which prefer thiazoline residues. The recognition sequence ‘RSIII’ places the core peptide (blue) in the active site as a result of salt bridge interactions with capping helices (CH, yellow). Serine residue at the active site attacks the carbonyl carbon linking the core peptide and recognition sequence to form an acyl-enzyme intermediate. Finally, the N-terminus attacks the ester to produce the cyclic peptide. In this study, we biochemically characterize proline specific macrocyclases.

PatG and its homologs are a class of remarkably promiscuous catalyst, with studies in vivo and in vitro revealing a broad tolerance to accept natural and unnatural amino acids.2628 Libraries encoding millions of products have been synthesized in Escherichia coli by TruG, a homolog of PatG from tru pathway.29 However, PatG has several limitations. It is a slow enzyme, at least under present conditions, and therefore disfavored substrates are impractical. PatG, and other macrocyclases that have been characterized so far, natively act on azolines. While proline and other heterocycles in artificial substrates is sometimes accepted by PatG, the reaction is usually much slower than it is with azoline.3031 Generally, azolines are installed by a specific cyanobactin heterocyclase enzyme prior to macrocyclization.32 Although the heterocycle provides rigidity to the backbone to assist macrocyclization, this additional biochemical step increases complexity and compromises the yield for downstream applications such as library generation.

Over the years, there has been an increasing number of cyanobactin biosynthetic gene families, which afford diverse, broad-substrate enzymes for synthetic biology.22, 3334 Among these is a group of cyclic cyanobactins that contain proline, rather than thiazoline, at the macrocyclization site. These pathways lack both azoline and the azoline-synthesizing heterocyclase enzyme, and thus might provide simpler macrocyclization catalysts. Unfortunately, no biochemical experiments for proline-specific cyclases have been reported, and in our hands, these enzymes have been challenging.

The first pathway for proline-selective cyanobactins was sequenced in 2009,35 and many more have since been identified, including the prenylagaramide (pag) pathway.34 Prenylagaramides, are a family of N-C cyclic, tyrosine O-prenylated peptides from Planktothrix agardhii cyanobacteria.36 Although pag has been cloned, only the PagF tyrosine O-prenyltransferase has been biochemically characterized.37 Here, we describe the characterization of PagG, a prolineselective macrocyclase that greatly expands accessible substrates for recombinant macrocyclases.

RESULTS AND DISCUSSION

PagG expression and in vitro activity

The pagG gene was codon-optimized and synthesized using the published sequence (GenBank accession number HQ655154).34 Despite attempting a wide variety of conditions, the full length PagG could not be produced in soluble form (Figures 2 and S1). The protein is comprised of an N-terminal protease/macrocyclase domain and a domain of unknown function (DUF) at the C-terminus.25 Previous experiments with PatG and TruG macrocyclases demonstrated that only the protease/macrocyclase domains were required for macrocyclization.30 The PagG macrocyclase domain (PagGmac) could be positively identified, expressed and purified, and this protein was used for all further experiments (Figures 3 and S1).

Figure 2.

Figure 2.

Proposed biogenesis of prenylagaramides. Precursor peptides are synthesized on the ribosome, and subsequently cleaved by PatA protease between RSII and the core peptide to release short substrates for macrocyclization (1-3). PatG protease cleaves the core peptide from RSIII (FAGDDAE), releasing the short peptide product and macrocyclizing the core peptides to yield products (4) and (5). Finally, the cyclic peptide is prenylated using DMAPP by enzyme PagF to produce the natural compounds, prenylagaramides C (6) and B (7).

Figure 3.

Figure 3.

in vitro PagG activity. (A) Extracted ion chromatograms of substrate 1 and product 4 at 0, 16 and 48 h of in vitro assay generated through LC/MS. (B) Extracted ion chromatograms of substrate 1 and product 4 at 16 h of in vitro assay with S274A/C275A, S274A and C275A generated through LC/MS. (C) Synthetic scheme for stepwise and one-pot reactions. (D) Extracted ion chromatograms of the reactant, intermediates and product involved in the synthetic scheme.

In the canonical cyanobactin biosynthesis, a precursor peptide is cleaved after RSII, liberating an amino group that is the nucleophile for the subsequent macrocyclization event. Once RSII is cleaved, the remaining short precursor peptide should be the substrate for PagGmac. It contains only the core peptide, encoding the natural product, and RSIII, which is recognized by PagGmac. Therefore, we used synthetic native substrates (1-3) with PagGmac (Figure 2A). Two of these substrates, 1 and 2, are natively converted into natural products (Figure 2), while the product of the third, 3, has not been isolated even though the precursor peptide is found in the P. aghardii genome.34 When 1 or 2 were treated with PagGmac, cyclic products 4 and 5 were obtained (Figure 3A), but substrate 3 was unreactive. Enzymatic reaction products 4 and 5 were compared with synthetic standards, confirming their structural identities (Figures S4-S8). These results showed that PagGmac was active, and that its activity reflected expectation for the wild-type enzyme.

Like PatG, PagGmac was a slow enzyme, with several hours required for significant product formation. Extensive reaction optimization was attempted, using different buffers, pH, temperature and additives (Figure S9), but velocity was not significantly improved. We speculate that conditions do not replicate what is found in the cytoplasm of cyanobacteria, and specifically that a better understanding of the role of DUFs may improve yield.

PagGmac active site mutational analysis

PatG and related macrocyclases are subtilisin-like serine proteases, which have been extensively characterized via mutagenesis and structural studies. PagGmac and its relatives share some similarities with PatG, including a similar predicted secondary structure and the Asp29-His113-Ser274 catalytic triad.25 However, there are no amino acids in the G proteases that predict whether the macrocyclase will prefer proline or azoline at the substrate’s C terminus. Additionally, there are several differences, including an unusual Cys275 in the active site adjacent to the nucleophilic Ser274 residue, while in PatG and relatives this residue is methionine (Figure S9). This is unique as both the serine and cysteine can act as a nucleophile for proteolysis, but cysteine has higher nucleophilicity due to the lower pKa of the sulfhydryl group.

The Ser274-Cys275 diad in the catalytic center was examined by simultaneously mutating both residues, to create seven point mutant proteins (Table 1, Figure S11). These mutants were assayed using linear substrate 1, and using mass spectrometry to quantify macrocyclic product 4. Product 4 was only observed when using mutants Cys275Ala, Cys275Ser, and Cys275Met. Thus, Ser274 is required, but Cys275 is not important for activity, ruling out the role of the sulfhydryl nucleophile in catalysis (Figures 3B and S12). Ser274 could not be substituted with Cys. This is similar to what has previously been found in studies of PatG: since sulfur is larger than oxygen, when the active-site Ser is replaced with Cys, a concomitant expansion of the active site is required.25 The active site mutants that showed macrocyclase activity were compared to the wild type enzyme through kinetic analysis (Table 1). The estimated kinetic parameters for the wild type enzyme and mutant Cys275Ala were only marginally different with kcat/KM (s−1mM−1) values of 1.0 and 0.8, respectively (Figure S13). However, mutants Cys275Ser and Cys275Met were far slower than wt PagGmac, with relative velocities compared to the wild type enzyme at constant substrate concentrations (Figure S13).

Table 1.

Representative kinetic parameters of PagGmac variants using substrate 1

Active Site Sequence Product kcat (s−1) Km (mM) kcat/KM (s−1 mM−1) Relative velocity
Wild type PagGmac 4 0.19 ± 0.04 0.18 ± 0.06 1.1 1
Ser274Ala/Cys275Ala - - - - -
Cys275Ala 4 0.32 ± 0.07 0.41 ± 0.11 0.8 1.27
Ser274Ala - - - - -
Ser274Cys/Cys275Ser - - - - -
Ser274Cys - - - - -
Cys275Ser 4 - - - 0.12
Cys275Met 4 - - - 0.19

in vitro reconstitution of pag pathway and formal total synthesis of prenylagaramide B & C

pag is predicted to encode three enzymes: PagA, which proteolyzes the precursor peptide to release substrates 1, and 2, PagG, which macrocyclizes linear peptides 1 and 2 to produce 4 and 5, and PagF, which prenylates 4 and 5 to produce the natural products 6 and 7 (Figure 2A).34 Since we used synthetic short substrates 1 and 2, pag would be reconstituted simply using PagGmac and PagF; PagA is not required. In a stepwise procedure, treatment of substrate 1 first with PagGmac and subsequently with PagF and dimethylallyl pyrophosphate (DMAPP) yielded the natural product 6, representing the first total synthesis of 6. In the second step in this procedure, the leftover substrate is also prenylated to form 8 (Figure 3).

A one-pot reaction containing all needed reagents failed because of the faster rate of PagF in comparison to PagGmac. Linear substrate 1 was prenylated prior to macrocyclization, yielding prenylated linear product 8. We found that the linear peptides, once prenylated, are no longer substrates for macrocyclase (Figure 3). This defines the biosynthetic order of the pag pathway, demonstrating that the proposed route shown in Figure 2 is correct (Figures S14 and S15).

Mutational analysis of the CH-RSIII interaction

Unlike canonical serine proteases, cyanobactin macrocyclases feature an additional CH, which binds to RSIII, enabling the macrocyclase to modify diverse core peptides.25, 38 This is a critical interaction that decouples the macrocyclase reaction from substrate recognition, making the enzymes ideal for biotechnology. The CH also stabilizes the tetrahedral orthoamide intermediates formed during the catalysis. Strikingly, when we compared the CH and RSIIIs from pag and related pathways, we observed entirely different sequence motifs, which further led to identification of a previously unremarked internal RS embedded within G-type cyanobactin macrocyclases (Figure 4 and S10).

Figure 4.

Figure 4.

Embedded RS in cyanobactin G enzymes. In the G enzymes, an embedded RS (emRS) is present downstream of the capping helix (CH), which binds the substrate RSIII. The emRS in the enzyme closely resembles the predicted or characterized RSIII in the cognate substrates. We hypothesize that the CH binds emRS in the absence of substrate (Figure S15)

In PatG, structural studies revealed that CH is comprised of residues Pro579-Val605, which aligned with Asp59-Lys98 in PagGmac. While PatG binds to RSIII elements with sequences similar to AYDGE/SYDD, PagGmac’s RSIII sequence is FAGDDAE. A close examination of the G protein sequence alignment showed that an embedded recognition sequence (emRS) is present downstream of the CHs. These observations prompted us to hypothesize that the emRS might bind to the cap in the absence of the substrate. (Figure S16). In previous macrocyclase crystal structures, the emRS region was unstructured.25, 38 Hence, further insights could not be drawn from the published studies.

To test the hypothesis, we expressed a series of chimeric PagGmac proteins wherein we swapped or added the PatG CH and emRS sequences (Table S8, Figure S17). Unfortunately, all constructs were soluble but inactive in our hands. In the D series of cyanobactin enzymes, recognition elements can be swapped among substrates using simple rules,39 but these rules are not as straightforward for the CH.

Broad substrate tolerance of PagGmac

PatG and relatives are exceptionally substrate-tolerant enzymes.29 It was unclear whether other cyanobactin G enzymes would exhibit similar tolerance. Therefore, we performed saturation mutagenesis on each position P2-P7 of substrate 2, leading to 114 unique peptide sequences and 6 duplicates of the native peptide sequence (Figure 5A). When treated with PagGmac, we found that ~60% of the substrates led to robust macrocyclization (Figure 5B). Only ~19% of the peptides remained unmodified by PagGmac. These results are similar to what has previously been found with PatG, indicating that PagGmac is a promising, broad-substrate catalyst. A few rules regarding the substrate tolerance of PagGmac could be discerned: acidic residues (Asp/Glu) are not tolerated at any position; positions P4-P6 are more accepting of variation than P2, P3, or P7.

Figure 5.

Figure 5.

PagGmac is a promiscuous catalyst. (A) A peptide library was synthesized in which each position P2 to P7 is independently mutated by each of the 20 proteinogenic amino acids. The library was arrayed into wells and treated with PagGmac, followed by PagF. The resulting macrocycles are shown schematically, with each accepted amino acid listed adjacent to each residue. (B) A heat map showing the acceptability of amino acids in positions P2 to P7 for macrocyclization by PagGmac. The heat map was generated using LC-MS traces for each reaction. Wild type residues are boxed in red.

Some of these rules make sense in light of the elegant PatG crystal structures. 25, 38 In the structure of the PatG complex with pentapeptide PIPFP, PatG causes the linear substrate to adopt a curved shape, bringing the N- and C-termini into proximity. In addition, the substrate P2 and P3 residues make limited van der Waals contact with the protein surface, while P4 and P5 make no contacts with PatG. Here, we observed that positions P4-P6 were more permissive, supporting the possibility that they have fewer contacts with PagGmac. We also propose that the inability to tolerate D/E in the core might be related to an incompatibility with the highly acidic RSIII sequence. Taken together, these rules will be useful in applying PagGmac to synthetic biology or drug design problems.

To validate the library approach, we performed a time course study with three randomly chosen peptides from the library using both wild-type PagGmac and the C275A active-site mutant. The reactions showed increasing product accumulation over 14 and 10 hours for the wild-type and mutant proteins, respectively (Figure S19). One recurring disadvantage of the macrocyclases from cyanobactins is that they are relatively slow. Here, we show that PagGmac has a comparable rate to the previously characterized thiazoline specific macrocyclases.30 However, its proline specificity may make it more useful than azoline-specific cyclases, since proline can be installed by universally available peptide chemistries. Further knowledge of internal mechanisms involving the DUF domain and capping helices may help to improve the relatively slow rates of these enzymes.

Substrate tolerance of PagF and use in library generation

Although PagF was previously characterized with several substrates, its application to cyclic peptide libraries has not been probed.37 We used the macrocyclization reaction library as substrates for PagF prenylation (Figures 5A and S18). Each well in the library contained the unreacted linear substrate peptides, as well as cyclic products where they could be formed as shown in Figure 5A. PagF modified virtually every peptide, as long as Tyr is present at P4 (the natively prenylated residue). Both cyclic and linear peptides were prenylated on Tyr at P4 position. Thus, PagF is also tolerant of significant sequence variation. By combining PagGmac and PagF, we synthesized a complex and chemically rich library of peptides modified by natural posttranslational enzymes.

PagGmac represents the first characterized representative of a new class of macrocyclases

Only a few of the cyanobactin cyclases have been previously characterized.23, 26, 34, 4041 We obtained 65 cyanobactin macrocyclase and related protein sequences, which are broadly representative of all cyanobactin G-proteins, and performed a Bayesian phylogenetic analysis (Figure 6). For many of the G protein sequences, we could also find substrate precursor peptides in the adjacent gene clusters and assign their functions based upon known natural products. Strikingly, these proteins grouped into clades that are based upon their natural substrate selectivity.3335, 4250 Our analysis thus identifies a series of catalysts that may be used to macrocyclize different types of peptides or peptide libraries. Among these, only four (including PagGmac) have been biochemically characterized, and only two (TruG and PagGmac) have been well characterized with defined substrate libraries. However, for many of the uncharacterized proteins, the known substrates and products are quite variable, indicating that broad substrate tolerance is a feature of cyanobactin G proteins.

Figure 6.

Figure 6.

Native chemical space of cyanobactin macrocyclases. Bayesian phylogenetic tree of 65 cyanobactin C-terminal protease/macrocyclases. For each of six color-coded enzyme classes, known product structures are shown. The C-terminal macrocyclization site in each product is indicated with a red bubble. Close observation shows that for all of the substrate selectivity “rules” observed for PagGmac or PatG / TruG, there are existing macrocyclases that break those rules and have complementary selectivity. Thus, judicious macrocyclase selection enables synthesis of diverse cycles. See Figure S19 for a complete tree with names and bootstrap values.

Phylogenetic analysis demonstrates that any gap in the substrate tolerance of PagGmac or TruG can be filled by the other classes (Figure 6). For example, PagGmac does not accept glycine, serine, or threonine at position P2, but those residues are found in the natural products of proline-specific macrocyclases from class VI. Peptides with proline at P4 position can be cyclized by class II macrocyclases (Figure 5B). Alternatively, TruG disfavors histidine at P3 or tyrosine at P4, but PagGmac processes such substrates (Figure S20).29 While acidic amino acids were not accepted by PagGmac, class II cyclase products contain those residues. Thus, for each limitation of PagGmac or TruG/PatG, there exists a cyclase that circumvents that limitation.

Moreover, several clades have no characterized representatives, and we cannot predict their substrates or products from available data. These represent promising areas for further biochemical research. Combined with macrocyclases from other classes of biosynthesis, there is a growing arsenal of enzymes to tackle challenging problems in macrocycle synthesis. The complete phylogenetic analysis is given in the supporting information (Figure S19).

A frontier of cyanobactin macrocyclases involves their demonstrated ability to circularize substrates that diverge significantly from ribosomal peptides, for example containing D-amino acids, polyketide-like spacers, and other nonproteinogenic components.2627 The substrate scope for non-protein cyclization cannot be discerned from the phylogenetic tree and requires experimental evidence.

CONCLUSION

We present the biochemical characterization and substrate tolerance profile of a new class of macrocyclase enzymes. We characterized the prenylagaramide biosynthetic pathway and synthesized natural products for the first time. Additionally, we used the tools from this pathway to generate a library of macrocyclic and prenylated peptides, demonstrating promising broad-substrate tolerance. We show that the natural cyclases group by substrate preference. Because of the many different macrocyclization catalysts available in this family, and the clear substrate rules delineated above, we predict that judicious choice of enzyme and substrate will enable the macrocyclization of virtually any linear compound.

Supplementary Material

Supplementary information

ACKNOWLEDGMENTS

This work was funded by NIH GM122521. S.S. is supported by the Skaggs Graduate Research Fellowship. We thank Elizabeth Pierce and Maho Morita for preparing the PagF enzyme and DMAPP substrate used in this study.

Footnotes

ASSOCIATED CONTENT

Supporting information

The Supporting Information is available free of charge on the ACS Publications website at DOI: https://pubs.acs.org/doi/10.1021/acscatal.0c00623.

Experimental methods, additional figures and tables (PDF)

Supporting Information Placeholder

The authors declare no competing financial interests.

REFERENCES

  • (1).Ermert P, Design, properties and recent application of macrocycles in medicinal chemistry. CHIMIA Int. J. Chem 2017, 71, 678–702. [DOI] [PubMed] [Google Scholar]
  • (2).Driggers EM; Hale SP; Lee J; Terrett NK, The exploration of macrocycles for drug discovery — an underexploited structural class. Nat. Rev. Drug Discov 2008, 7, 608. [DOI] [PubMed] [Google Scholar]
  • (3).Mallinson J; Collins I, Macrocycles in new drug discovery. Future Med. Chem 2012, 4, 1409–1438. [DOI] [PubMed] [Google Scholar]
  • (4).Sytniczuk A; Dąbrowski M; Banach Ł; Urban M; Czarnocka-Śniadała S; Milewski M; Kajetanowicz A; Grela K, At long last: olefin metathesis macrocyclization at high concentration. J. Am. Chem. Soc 2018, 140, 8895–8901. [DOI] [PubMed] [Google Scholar]
  • (5).Shen X; Nguyen TT; Koh MJ; Xu D; Speed AWH; Schrock RR; Hoveyda AH, Kinetically E-selective macrocyclic ring-closing metathesis. Nature 2017, 541, 380–385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (6).Blackwell HE; Sadowsky JD; Howard RJ; Sampson JN; Chao JA; Steinmetz WE; O’Leary DJ; Grubbs RH, Ring-closing metathesis of olefinic peptides:  design, synthesis, and structural characterization of macrocyclic helical peptides. J. Org. Chem 2001, 66, 5291–5302. [DOI] [PubMed] [Google Scholar]
  • (7).Turner RA; Oliver AG; Lokey RS, Click chemistry as a macrocyclization tool in the solid-phase synthesis of small cyclic peptides. Org. Lett 2007, 9, 5011–5014. [DOI] [PubMed] [Google Scholar]
  • (8).Pasini D, The click reaction as an efficient tool for the construction of macrocyclic structures. Molecules 2013, 18, 9512–9530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (9).Angell Y; Burgess K, Ring Closure to β-turn mimics via copper-catalyzed azide/alkyne cycloadditions. J. Org. Chem 2005, 70, 9595–9598. [DOI] [PubMed] [Google Scholar]
  • (10).Nicolaou KC; Boddy CNC, Atropselective macrocyclization of diaryl ether ring systems: application to the synthesis of vancomycin model systems. J. Am. Chem. Soc 2002, 124, 10451–10455. [DOI] [PubMed] [Google Scholar]
  • (11).Meutermans WDF; Bourne GT; Golding SW; Horton DA; Campitelli MR; Craik D; Scanlon M; Smythe ML, Difficult macrocyclizations:  new strategies for synthesizing highly strained cyclic tetrapeptides. Org. Lett 2003, 5, 2711–2714. [DOI] [PubMed] [Google Scholar]
  • (12).Tavassoli A; Benkovic SJ, Split-intein mediated circular ligation used in the synthesis of cyclic peptide libraries in E. coli. Nat. Protoc 2007, 2, 1126–1133. [DOI] [PubMed] [Google Scholar]
  • (13).White CJ; Yudin AK, Contemporary strategies for peptide macrocyclization. Nat. Chem 2011, 3, 509–524. [DOI] [PubMed] [Google Scholar]
  • (14).Chang TK; Jackson DY; Burnier JP; Wells JA, Subtiligase: a tool for semisynthesis of proteins. Proc. Natl. Acad. Sci. U. S. A 1994, 91, 12544–12548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (15).Weeks AM; Wells JA, Subtiligase-catalyzed peptide ligation. Chem. Rev 2019. [DOI] [PubMed] [Google Scholar]
  • (16).Houssen WE, Peptide cyclization catalyzed by cyanobactin macrocyclases In Enzyme-mediated ligation methods, Nuijens T; Schmidt M, Eds.; Springer NY: New York, 2019; 193–210. [DOI] [PubMed] [Google Scholar]
  • (17).de Veer SJ; Kan MW; Craik DJ, Cyclotides: from structure to function. Chem. Rev 2019, 119, 12375–12421. [DOI] [PubMed] [Google Scholar]
  • (18).Gould A; Camarero JA, Cyclotides: overview and biotechnological applications. ChemBioChem 2017, 18, 1350–1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (19).Poth AG; Colgrave ML; Philip R; Kerenga B; Daly NL; Anderson MA; Craik DJ, Discovery of cyclotides in the fabaceae plant family provides new insights into the cyclization, evolution, and distribution of circular proteins. ACS Chem. Biol 2011, 6, 345–355. [DOI] [PubMed] [Google Scholar]
  • (20).Harris KS; Durek T; Kaas Q; Poth AG; Gilding EK; Conlan BF; Saska I; Daly NL; van der Weerden NL; Craik DJ; Anderson MA, Efficient backbone cyclization of linear peptides by a recombinant asparaginyl endopeptidase. Nat. Commun 2015, 6, 10199–10199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (21).Gu W; Dong S-H; Sarkar S; Nair SK; Schmidt EW, The biochemistry and structural biology of cyanobactin pathways: enabling combinatorial biosynthesis. Methods Enzymol. 2018, 604, 113–163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (22).Sivonen K; Leikoski N; Fewer DP; Jokela J, Cyanobactins-ribosomal cyclic peptides produced by cyanobacteria. Appl. Microbiol. Biotechnol 2010, 86, 1213–1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (23).Lee J; McIntosh J; Hathaway BJ; Schmidt EW, Using marine natural products to discover a protease that catalyzes peptide macrocyclization of diverse substrates. J. Am. Chem. Soc 2009, 131, 2122–2124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (24).Schmidt EW; Nelson JT; Rasko DA; Sudek S; Eisen JA; Haygood MG; Ravel J, Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proc. Natl. Acad. Sci. U. S. A 2005, 102, 7315–7320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (25).Agarwal V; Pierce E; McIntosh J; Schmidt, Eric W.; Nair, Satish K., Structures of cyanobactin maturation enzymes define a family of transamidating proteases. Chem. Biol 2012, 19, 1411–1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (26).McIntosh JA; Robertson CR; Agarwal V; Nair SK; Bulaj GW; Schmidt EW, Circular logic: nonribosomal peptide-like macrocyclization with a ribosomal peptide catalyst. J. Am. Chem. Soc 2010, 132, 15499–15501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (27).Oueis E; Nardone B; Jaspars M; Westwood NJ; Naismith JH, Synthesis of hybrid cyclopeptides through enzymatic macrocyclization. ChemistryOpen 2017, 6, 11–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (28).Oueis E; Jaspars M; Westwood NJ; Naismith JH, Enzymatic macrocyclization of 1,2,3-triazole peptide mimetics. Angew. Chem., Int. Ed 2016, 55, 5842–5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (29).Ruffner DE; Schmidt EW; Heemstra JR, Assessing the combinatorial potential of the RiPP cyanobactin tru pathway. ACS Synth. Biol 2015, 4, 482–492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (30).Sardar D; Lin Z; Schmidt, Eric W., Modularity of RiPP enzymes enables designed synthesis of decorated peptides. Chem. Biol 2015, 22, 907–916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (31).Oueis E; Stevenson H; Jaspars M; Westwood NJ; Naismith JH, Bypassing the proline/thiazoline requirement of the macrocyclase PatG. Chem. Commun 2017, 53, 12274–12277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (32).McIntosh JA; Schmidt EW, Marine molecular machines: heterocyclization in cyanobactin biosynthesis. ChemBioChem 2010, 11, 1413–1421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (33).Donia MS; Ravel J; Schmidt EW, A global assembly line to cyanobactins. Nat. Chem. Biol 2008, 4, 341–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (34).Donia Mohamed S.; Schmidt Eric W., Linking chemistry and genetics in the growing cyanobactin natural products family. Chem. Biol 2011, 18, 508–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (35).Leikoski N; Fewer DP; Jokela J; Wahlsten M; Rouhiainen L; Sivonen K, Highly diverse cyanobactins in strains of the genus Anabaena. Appl. Environ. Microbiol 2010, 76, 701–709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (36).Murakami M; Itou Y; Ishida K; Shin HJ, Prenylagaramides A and B, new cyclic peptides from two strains of Oscillatoria agardhii. J. Nat. Prod 1999, 62, 752–755. [DOI] [PubMed] [Google Scholar]
  • (37).Hao Y; Pierce E; Roe D; Morita M; McIntosh JA; Agarwal V; Cheatham TE; Schmidt EW; Nair SK, Molecular basis for the broad substrate selectivity of a peptide prenyltransferase. Proc. Natl. Acad. Sci. U. S. A 2016, 113, 14037–14042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (38).Koehnke J; Bent A; Houssen WE; Zollman D; Morawitz F; Shirran S; Vendome J; Nneoyiegbe AF; Trembleau L; Botting CH; Smith MCM; Jaspars M; Naismith JH, The mechanism of patellamide macrocyclization revealed by the characterization of the PatG macrocyclase domain. Nat. Struct. Mol. Biol 2012, 19, 767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (39).Sardar D; Pierce E; McIntosh JA; Schmidt EW, Recognition sequences and substrate evolution in cyanobactin biosynthesis. ACS Synth. Biol 2015, 4, 167–176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (40).Sardar D; Hao Y; Lin Z; Morita M; Nair SK; Schmidt EW, Enzymatic N- and C-protection in cyanobactin RiPP natural products. J. Am. Chem. Soc 2017, 139, 2884–2887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (41).Alexandru-Crivac CN; Umeobika C; Leikoski N; Jokela J; Rickaby KA; Grilo AM; Sjö P; Plowright AT; Idress M; Siebs E; Nneoyi-Egbe A; Wahlsten M; Sivonen K; Jaspars M; Trembleau L; Fewer DP; Houssen WE, Cyclic peptide production using a macrocyclase with enhanced substrate promiscuity and relaxed recognition determinants. Chem. Commun 2017, 53, 10656–10659. [DOI] [PubMed] [Google Scholar]
  • (42).Ishida K; Matsuda H; Murakami M; Yamaguchi K, Kawaguchipeptin A, a novel cyclic undecapeptide from cyanobacterium Microcystis aeruginosa (NIES-88). Tetrahedron 1996, 52, 9025–9030. [DOI] [PubMed] [Google Scholar]
  • (43).Ishida K; Matsuda H; Murakami M; Yamaguchi K, Kawaguchipeptin B, an antibacterial cyclic undecapeptide from the cyanobacterium Microcystis aeruginosa. J. Nat. Prod 1997, 60, 724–726. [DOI] [PubMed] [Google Scholar]
  • (44).Leikoski N; Fewer DP; Jokela J; Alakoski P; Wahlsten M; Sivonen K, Analysis of an inactive cyanobactin biosynthetic gene cluster leads to discovery of new natural products from strains of the genus Microcystis. PLoS One 2012, 7, e43002–e43002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (45).Leikoski N; Liu L; Jokela J; Wahlsten M; Gugger M; Calteau A; Permi P; Kerfeld, Cheryl A.; Sivonen, K.; Fewer, David P., Genome mining expands the chemical diversity of the cyanobactin family to include highly modified linear peptides. Chem. Biol 2013, 20, 1033–1043. [DOI] [PubMed] [Google Scholar]
  • (46).Lin Z; Torres JP; Tianero MD; Kwan JC; Schmidt EW, Origin of chemical diversity in prochloron-tunicate symbiosis. Appl. Environ. Microbiol 2016, 82, 3450–3460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (47).Martins J; Leikoski N; Wahlsten M; Azevedo J; Antunes J; Jokela J; Sivonen K; Vasconcelos V; Fewer DP; Leão PN, Sphaerocyclamide, a prenylated cyanobactin from the cyanobacterium Sphaerospermopsis sp. LEGE 00249. Sci. Rep 2018, 8, 14537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (48).Portmann C; Blom JF; Gademann K; Jüttner F, Aerucyclamides A and B: isolation and synthesis of toxic ribosomal heterocyclic peptides from the cyanobacterium Microcystis aeruginosa PCC 7806. J. Nat. Prod 2008, 71, 1193–1196. [DOI] [PubMed] [Google Scholar]
  • (49).Portmann C; Blom JF; Kaiser M; Brun R; Jüttner F; Gademann K, Isolation of aerucyclamides C and D and structure revision of microcyclamide 7806A: heterocyclic ribosomal peptides from Microcystis aeruginosa PCC 7806 and their antiparasite evaluation. J. Nat. Prod 2008, 71, 1891–1896. [DOI] [PubMed] [Google Scholar]
  • (50).Shin HJ; Matsuda H; Murakami M; Yamaguchi K, Agardhipeptins A and B, two new cyclic hepta- and octapeptide, from the cyanobacterium Oscillatoria agardhii (NIES-204). Tetrahedron 1996, 52, 13129–13136. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary information

RESOURCES